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This review focuses on nasal and pulmonary delivery of NSAIDs (non-steroidal anti-
inflammatory drugs) for fast-onset analgesia, for the potential prevention of Alzheimer’s 
disease (AD), as well as for an add-on treatment in cystic fibrosis (CF) and non-small cell 
lung cancer (NSCLC). I discuss how the physicochemical properties of NSAIDs can be 
modified with respect to the biological characteristics of the target site. Innovative technology 
and/or dosage forms can promote an effective therapy.
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NSAIDs in therapy  
The large family of NSAIDs are frequently used as analgesics, anti-inflammatory and 
antipyretic agents. Their biological effects are explained by the inhibition of the 
cyclooxygenase (COX) enzymes, which are responsible for the biosynthesis of prostaglandins 
that promote pain and inflammation. COX enzymes have 3 different isoforms: COX-1 is 
constitutively expressed in most healthy tissues, while COX-2 is an inducible form expressed 
in inflammatory cells in response to proinflammatory stimuli such as injury, bacterial 
endotoxins, tumor-promoting agent, etc. The newly discovered isoform COX-3 which is a 
variant of COX-1 is produced particularly in the brain [1].  Based on their selectivity, 
NSAIDs are (i) nonselective COX-1/COX-2 inhibitors, (ii) preferential COX-2 inhibitors with 
5-50-fold selectivity and (iii) COX-2 inhibitors with >50-fold selectivity. NSAIDs are also 
classified according to their chemical structures and anti-inflammatory activities (Table 1) [2].
As shown is table 1 non-selective COX inhibitors include acetylsalicylic acid, indomethacin, 
aryl propionic acid derivatives, diclofenac, and naproxen. They have a long history as 
analgesics for acute or chronic pain (headache, migraine, menstrual, metastatic bone 
associated and postoperative pain, etc.), and also as antipyretics, as well as anti-inlammatory 
treatment for rheumatoid diseases. Nimesulide, meloxicam, and etodolac were the first 
NSAIDs with an enhanced safety profile, used as strong anti-inflammatory agents and later 
considered as preferential COX-2 inhibitors. 
In fact, the COX-2 isoform was discovered in the early 1990s, and COX-2 inhibitors such as 
celecoxib, rofecoxib and etoricoxib possessing high selectivity and an increased inhibitory 
effect were approved. These agents were investigated in several inflammatory conditions such 
as non-rheumatoid inflammation, rheumatoid arthritis, osteoarthritis, spondylitis, add-on 
cancer treatment and prevention, and migraine [3]. Both COX-1 and COX-2 inhibitors are 
tested in brain pathologies including Alzheimer’s and Parkinson’s disease, as well colorectal 
and breast cancers [4]. 
COX-1/COX-3 inhibitors may include paracetamol (acetaminophen), phenacetin and 
aminophenazone which are generally not considered NSAIDs because they have little anti-
inflammatory activity. They reduce pain and fever, mostly in the central nervous system 
(CNS), and exert little effect in the rest of the body [1]
Physicochemical profiles of NSAIDs
Most of the NSAIDs are strong organic acids (carboxylic acids) with a dissociation constant 
(pKa) of 2–5 (but for some agents it may be ʽ10) (Table 1). Their water solubility is pH-
dependent, and in general it is poor or very poor. The acidic group is essential for the COX 
inhibitory activity. 
NSAIDs differ in their lipophilic character wich is influenced by their aryl groups and 
additional lipophilic moieties and substituents. They are characterized by their ʽpartition 
coefficient’ which is a measure of how well the agent partitions between the lipid (oil) and 
water phases. Measured or calculated values are given in a database as logP (logarithm of 
octanol/water partition coefficient). When combined with pKa, it predicts the distribution of 
the compound in a biological system (logD, logarithm of octanol/water distribution 
coefficient e.g. at pH 7.4). 
As NSAIDs basically have a lipophilic character, their permeability through membranes is 
„good” according to BCS (Biopharmaceutical Classification System) [5]. Most NSAIDs 
belong to Class II agents with low solubility and high permeability, and exhibit dissolution 
rate-limited absorption. 
Routes of administration
Worldwide, approximately 30 million people use NSAIDS daily. Tablets and capsules are 
popular dosage forms for oral administration, but are often associated with gastrointestinal 
side effects, mainly because of their acidic character [6, 7]. Other well-known routes of 
administration include injections, transdermal delivery systems and topical dosage forms. The 
poor solubility of NSAIDs gives grounds for different technological formulations to enhance 
their activity and reduce side-effects [8]. Nasal and pulmonary application are new 
approaches of significant therapeutic potential. However, based on the targeted biological 
environment, these routes of administration require the modification of the physicochemical 
characteristics of NSAIDs.
Nasal application of NSAIDs
Intranasal administration is an effective way to deliver drugs into the systemic circulation as 
an alternative to the oral and parenteral routes for some therapeutic agents (Fig. 1 and Table 
1). The nasal pathway may bypass the blood–brain barrier and allow centrally acting 
pharmacons to directly enter the CNS [9]. The main advantages of nasal administration 
include (i) a relatively large absorption surface, (ii) escaping first-pass elimination, (iii) a 
rapid onset of action, and (iv) non invasive and easy administration, offering improved 
compliance [8].  
As NSAIDs are poorly dissolved at the nasal membrane (pH: 5.3-5.6), increasing their 
solubility and/or the rate of dissolution is a challenge to overcome in the development of nasal 
dosage forms, in order to enhance bioavailability (Table 1).  Solubility may be improved by 
using salt forms, solubility-enhancing agents such as co-solvents (e.g. benzyl alcohol) or 
complexing agents (e.g. cyclodextrins). The dissolution rate may be increased by particle size 
reduction to the micro- or nano range [10] or by breaking of crystal structure (amorphous 
form, applicable for a liquid or gel form containing the suspended active agent). Also, the 
residence time, i.e. the length of time the formulation spends in the nasal cavity should be 
lengthened by using mucoadhesive agents [11]. 
Analgesia
So far, the first and only intranasal NSAID product available in the market was approved by 
the US Food and Drug Administration in 2010 (SprixR, Regency Therapeutics, Shirley, NY, 
USA, current MAH: Egalet Corporation, Wayne, PA, USA). It contains the salt form of 
ketorolac (ketorolac tromethamine) and is indicated in adult patients for the short term (up to 
5 days) management of moderate to moderately severe pain that requires analgesia at the 
opioid level The pivotal phase III study supporting its approval showed that patients required 
34 percent less morphine within the first 24 hours following hysterectomy and hip 
replacement surgery compared to patients on on-demand postoperative morphine alone [12]. 
Currently, the results of a phase IV study comparing ketorolac tromethamine nasal spray with 
a sumatriptan nasal spray and placebo for the acute treatment of migraine, are under 
evaluation [13]. 
Based on literature data, meloxicam as a preferential selective COX-2 inhibitor could be a 
new candidate for nasal application to induce rapid-onset analgesia. For an enhanced nasal 
absorption, its salt form, meloxicam potassium monohydrate has been investigated [14]. Both 
in vitro and in vivo results indicate that this salt form is preferable for the development of an 
intranasal liquid dosage form. Besides, a nasal formulation of dissolved meloxicam, 
containing different solubility enhancers was patented by Castile et al. [15]. 
The solubility of meloxicam can be increased by over 270-fold, from 4.4 µg/mL to 
1.2 mg/mL via nanonization (particle size ʽ200 nm) and using solubilizing agents [16], 
resulting in a significant improvement of pharmacokinetic characteristics. In vitro and in vivo 
studies indicate that the longer residence time and the uniform distribution of nanonized 
meloxicam sprayed on the nasal mucosa result in better absorption and a higher AUC [17-19].
Alzheimer’s disease (AD)
AD is a chronic neurodegenerative disease associated with a chronic neuroinflammatory 
environment in the brain [20, 21]. Observational epidemiological studies indicate that long-
term oral administration of NSAIDs to patients having rheumatoid arthritis may reduce the 
risk and delay the onset of AD [22]. Therefore, NSAIDs might play a role in the prevention of 
AD. However, as only 1-2% of total NSAID plasma concentration reaches the brain, it is 
considered that intranasal administration would significantly increase the drug dose entering 
the brain [23, 24].
Experimental studies show that AD starts in the entorhinal cortex which is connected to the 
olfactory nerves, and spreads in an anatomically defined pattern [25]. Therefore, a nasal 
NSAID would readily reach the brain region where it is the most likely to be of therapeutic 
benefit [25].
Low-molecular-weight lipophilic drugs are fast absorbed into the brain via the intranasal route 
[26]. Parepally et al. [27] investigated the brain uptake of ibuprofen, flurbiprofen, and 
indomethacin. Flurbiprofen was found to be preferable to ibuprofen because of its 12.5-fold 
potency [28, 29]. Also, flurbiprofen inhibits both COX-1 and COX-2, thus it may be more 
effective than selective COX-2 inhibitors [30].
Pulmonary application of NSAIDs
Pulmonary application is a non-invasive method of drug delivery for systemic or local 
respiratory effects (Fig. 2). It usually allows for a reduction of drug dose compared to oral or 
parenteral adminstration. Inhalation delivery of NSAIDs can be especially useful for the 
treatment of cystic fibrosis (CF) and non-small cell lung cancer (NSCLC). 
The main advantages of pulmonary administration include (i) the large surface of conducting 
airways of about 0.8 m2, (ii) an effective local therapy, (iii) limited penetration into the 
systemic circulation resulting in less side effects, (iv) non-invasive, easy administration 
offering good compliance (Table 2).
The physicochemical properties of NSAIDs allow for pulmonary application as an aerosol, 
which is a two-phase system containing solid particles or liquid droplets dispersed in air or 
other gas phase. Solid particles may be administered in a dry powder inhaler (DPI) system, 
while liquid preparations contain the drug in a dissolved form. Both are suitable for NSAIDs 
as they are properly soluble at pH 7.4 of the lungs, offering a good therapeutic effect. NSAIDs 
are also ideal for inhalation because they have small molecule weight and a relatively high 
logP value [31].
To enhance the deposition and thus the bioavailability of NSAIDs from pulmonary 
formulations, we need to ensure (i) a controllable particle/droplet morphology (size, surface), 
(ii) a narrow interval in particle size distribution, (iii) low bulk density of solid particles, (iv) 
an ideal aerodynamical property of particles, (v) a high fine-particle fraction, a small mass 
median aerodynamic diameter and a high emitted dose, as well as (vi) long residence time 
provided by mucoadhesive agents [32] (Table 2). Different additives (surfactants, polymers, 
etc.) may also be used to produce drug delivery systems with a better and faster effect.
Cystic fibrosis (CF)
CF is a genetic disorder characterized by build up of thick, sticky mucus mostly in the lungs, 
but also in other organs (e.g. pacreas, liver, kidneys, intestine, etc). CF mucus contains less 
water, and mucins with a special cross-linked structure, resulting in high viscoelasticity. Ruge 
et al. reported that the pore size of CF mucus falls into the nano-size range. As pulmonary 
drug delivery requires permeation through the porous sticky mucus layer [33], inhalable 
nanostructured particles (ʽ1000 nm) are the suitable choice for an effective penetration [34]. 
NSAIDs must be evenly distributed throughout the airways and the alveolar tissue that 
contain a wealth of inflammatory cells [35].
Different NSAIDs (ibuprofen, indomethacin, diclofenac sodium) have been investigated for 
inhalation [36]. So far, ibuprofen (per os) is the only NSAID approved for chronic use in CF, 
as it was found to slow the progression of lung disease in children [37].  In case of pulmonary 
delivery, its dose is four to five times less compared to conventional high dose oral therapy. 
Sheikh at al. reviewed the role of NSAIDs in CF treatment, and concluded that an inhalable 
form of ibuprofen, either alone or in combination with an antibiotic, could hold the potential 
to revolutionize the therapeutic approaches for CF, and may also reduce the treatment burden 
of the CF community in the long term [38]. Ibuprofen-containing formulations with a high 
drug loading capacity and less added polymers have been investigated, and were found to be 
characterized by an increased cellular uptake and enhanced mucus penetration [39]. Ibuprofen 
in combination with an antibiotic (ciprofloxacin) and mannitol formulated by a co-spray 
drying technique resulted in enhanced mucus clearance and suppressed local chronic infection 
[40]. Meloxicam-containing carrier-free and carrier-based compositions in the micro- and 
nano-size range have also been tested and may offer new treatment alternatives in CF [32].
Non-small cell lung cancer (NSCLC) 
NSCLC is the most common type of lung cancer. COX-2 is selectively overexpressed in 
neoplastic and inflammatory tissues. NSCLC overexpresses COX-2, which contributes to the 
progression of malignancy by several mechanisms which represents the basis for the potential 
efficacy of COX-2 inhibitors in terms of induction of apoptosis, inhibition of angiogenesis, 
and decreased invasiveness and metastatic potential [41]. Tsubouchi et al. evaluated the 
effects of meloxicam on lung cancer cells’ proliferation, and concluded that meloxicam may 
be useful add-on therapeutic agent in the treatment of NSCLC [42].  
In preclinical studies the COX-2 inhibitors celecoxib and rofecoxib, as well as meloxicam as a 
preferential COX-2 inhibitor were investigated to improve the efficacy of NSCLC therapy 
[43].  Compared with coxibs, meloxicam has reduced cardiovascular toxicity; however, its 
anti-tumor efficacy has not been proved in clinical settings. In a phase II study the 
combination of meloxicam, carboplatin, and docetaxel were tested in patients with advanced 
NSCLC. Meloxicam added to carboplatin plus docetaxel demonstrated acceptable tolerability 
with encouraging activity in advanced NSCLC patients. It should be noted, that patients 
received oral meloxicam (150 mg daily). Similarly, in another study the addition of meloxican 
(per os) was reported to enhance the reponse to paclitaxel/carboplatin in patients with 
advanced NSCLC [44]. As the oral dose is much higher than what would be required for an 
effective pulmonary effect, the inhaled dose should be considered for the combination therapy 
of NSCLC.
Conclusion 
The therapeutic effects of NSAIDs are determined by their physicochemical properties. 
Successful nasal application requires the increase of solubility by using the salt forms or using 
penetration enhancers. Also, micronization and nanonization of the active agent may increase 
the extent of dissolution for a fast onset of analgesia or to target the brain to potentially 
prevent the development of AD. In case of pulmonary application, modifying the 
physicochemical properties of NSAIDs is not enough alone, because the pathological lung 
condition requires special formulations to ensure a targeted anti-inflammatory effect in CF 
and NSCLC. Nasal and pulmonary administration of NSAIDs is promising, but further studies 
are needed to characterize their therapeutic efficiency and to optimize their formulations. 
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Figure captions
Figure 1 Nasal administration of NSAIDs to reach the blood and the brain
Figure 2 Figure 2 Pulmonary administration of NSAIDs for potential use in CF and NSCLC therapy
 Table 1. Chemical classification and physicochemical characteristics of the most important NSAIDs *
Derivative Drug Selectivity pKa logP Solubility in water  
at 25 °C (mg/L)
Salicylates Acetylsalicylic 
acid
1non-selective 3.49 1.19 4600.0
Acetic acid 
derivates
Indomethacin
Diclofenac 
Aceclofenac
Sulindac
Etodolac
Ketorolac
1non-selective
1non-selective
1non-selective
1non-selective
2COX-2 preferential
1non-selective
4.50
4.15
3.44
4.70
4.65
3.84
4.27
4.51
2.17
3.42
2.50
2.66
0.94
2.37
2.00
3000.0
16.0
513.0
Oxicams/enol 
acid derivatives
Piroxicam
Tenoxicam
Meloxicam
1non-selective
1non-selective
2COX-2 preferential
6.03
2.21
4.08
3.06
1.90
3.43
23.0
14.1
7.15
Propionic acid 
derivatives
Ibuprofen
Flurbiprofen
Ketoprofen
Naproxen
1non-selective
1non-selective
1non-selective
1non-selective
4.91
4.42
4.45
4.15
3.97
4.16
3.12
3.18
21.0
8.00
51.00
15.90
Fenamic acid 
derivatives
Mefenamic acid
Flufenamic acid
1non-selective
1non-selective
4.20
3.88
5.12
5.25
20.00
9.09
Arylsulfonamide Nimesulid 2COX-2 preferential 6.86 2.60 18.00
Coxibs Celecoxib
Rofecoxib
Etoricoxib
3COX-2 selective
3COX-2 selective
3COX-2 selective
10.07
14.84
19.69
3.90
3.20
3.70
3.30
11.00
3.00
Anilids,
Pyrazolone
Paracetamol
Phenacetin
Aminophenazon
COX-3 inhibitor
COX-3 inhibitor
COX-3 inhibitor
9.38
14.98
5.00
0.46
1.58
1.0
4150.0
766.0
25.50
1non-selective: COX-1/COX-2 inhibitor
2COX-2 preferential: drugs that inhibit COX-2 at lower concentrations than COX-1 (5-50-fold selectivity)
3COX-2 selective: drugs that inhibit COX-2 (but not COX-1) at label dose (> 50-fold selectivity)
*DrugBank (http://www.drugbank.ca/drugs)
Table 2. Biological factors to be considered with respect to the route administration, and related 
physicochemical properties of NSAIDs 
Nasal therapy
Biological factors 
-Healthy nose-
Physicochemical properties
-NSAIDs-
- Mucociliary clearence
- Permeability
- pH 
- Absorption
- Membrane thickness and surface
- Barrier with tight junctions
- Enzime activity
- Solubility
- Dissolution rate
- logP
- pKa
- Particle-size distribution
- Products:  
 Liquid form (use of salt form, 
solubilizing agent)
 Gel form (polymer based carrier system)
 Dry powder form (micro- and 
nanoparticles)
Pulmonary therapy
Biological factors
- Unhealthy lung-
Physicochemical properties
-NSAIDs-
- Mucociliary clearence
- Permeability
- pH
- Enzime activity
- Rheological characteristic
  (mucus)
- Mucus thickness
- Lung development
- Bacterial colonization
- Cell types per lung region
- Cell growth
- Solubility
- Dissolution rate
- logP
- pKa
- Density
- Particle-size distribution
- Aerodynamical properties of particles
- Products:
 Liquid form (solution)
 Dry Powder Inhaler (DPI)
                  (carrier-free and carrier-based form)
